MDM2 and cancer: Nearly half (49%) of urothelial bladder cancers had TP53 mutations, and 76% of the cancers had inactive TP53 functions [101] because their relationship with the amplification (9%) and overexpression (29%) of MDM2 was mutually exclusive.